Resources Library

GET RESOURCE

Please provide the requested details below to download the document.

PRECISE II (U.S.) TRIAL – 2016

PRECISE II (U.S.) TRIAL – 2016

The second study (Precise II) included 90 participants with Type 1 and Type 2 diabetes. It was performed in the United States and demonstrated the efficacy and safety of the Eversense CG System during 90 days of continuous sensor wear.

Related Resources

Infographic
EVERSENSE AT A GLANCE

Check out this graphic overview of the…

Interactive Module
FUNDAMENTALS OF CGM

Learn more about how continuous glucose…

Video
HOW TO GET STARTED

Get started with your new Eversense 90-day,…